Navigation Links
Emisphere Announces Data From Independent Clinical Study of Effects of Oral GLP-1 on Glucose and Insulin Concentrations
Date:7/8/2008

GLP-1 Has Potential to Treat Type 2 Diabetes Using Emisphere's Eligen(R)

Technology

CEDAR KNOLLS, N.J., July 8 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced findings from a clinical study assessing the oral delivery of GLP-1 peptide safely and effectively. The study used a delivery-agent-based approach using Emisphere's Eligen(R) technology, and was conducted at University Hospital in Basel, Switzerland by Christoph Beglinger, M.D., of the Clinical Research Center, Department of Biomedicine Division of Gastroenterology, and Department of Clinical Pharmacology and Toxicology at the hospital.

Prof. Beglinger's study, conducted in 16 healthy male subjects, was designed to explore the pharmacodynamic effects of a single oral dose of GLP-1 administered 15 minutes prior to an oral glucose tolerance test.

For the study, GLP-1 was formulated as a tablet with Emisphere's delivery agent known as SNAC. This was Prof. Beglinger's second clinical study of the compound, and it confirmed his earlier results that SNAC allows for rapid oral absorption of GLP-1. Prof. Beglinger's study also showed that pharmacological levels were achieved after a 2 mg oral dose. The study demonstrated that the oral formulation of GLP-1 stimulated an early increase in fasting insulin and a decrease in fasting glucose as compared to placebo.

"An intravenous or subcutaneous application of GLP-1 is cumbersome and impractical for chronic treatment regimens. Oral application of peptides is, however, difficult as peptides have a low oral bioavailability due to their molecular size and physico-chemical characteristics," said Prof. Beglinger. "Emisphere's oral delivery approach has
'/>"/>

SOURCE Emisphere Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
2. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
3. Emisphere Technologies Announces Positive Results From Animal Studies on Oral B12 Using eligen(R) Technology
4. Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses
5. Proof of Concept Study in Second Species Demonstrates Increase in Absorption of Oral B12 Using Emisphere Technology
6. Emisphere Technologies Announces the Launch of a Human Clinical Trial For Oral Parathyroid Hormone (PTH)
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...ire-FirstCall/ -- Hologic, Inc. (Hologic or the Co...facturer and supplier of premium diagnostics, medi...d to serving the healthcare needs of women, is usi...of North America (RSNA) at McCormick Place in Chic...ight our new SecurView(®) DX multimodality di...
(Date:11/25/2009)...- BioTrends Research Group, Inc. released Wave 1 o...e first in a multi-phase syndicated market researc...otech,s Stelara, from product launch through the f... report provides quantitative information from 75 ...from a subset of 20. The reports assess trial and...
(Date:11/25/2009)...Newswire/ -- AMPAC Fine Chemicals LLC (AFC), a sub...APFC ) announced today that it received the Enviro... the Annual Statewide Environmental Summit, sponso... Association (CMTA), the Industrial Environmental ...l of California (CICC) held in San Diego. This is...
Breaking Medicine Technology:New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 2New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 3New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 4Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 2AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 3Plant protein doorkeepers block invading microbes study finds 9155 1Plant protein doorkeepers block invading microbes study finds 9155 2Plant protein doorkeepers block invading microbes study finds 9155 3Scientists closer to developing salt tolerant crops 9152 1Scientists closer to developing salt tolerant crops 9152 2Perot Systems Launches Website in Chinese to Support Expansion Into China 51016 1Perot Systems Launches Website in Chinese to Support Expansion Into China 51016 2
...rospective,analysis of healthcare claims in more t...ntegrated U.S. national managed care database foun...lin glargine was associated with,a lower incidence...,compared with NPH insulin. The new findings, pres...entific Sessions, are some of the first to,evaluat...
... Dose-Dependent in Sub-Analysis of Phase II ...a., Nov. 7 SCH 530348 (TRA), the,novel investigat...g-Plough,Corporation (NYSE: SGP ), was shown to b...sub-analysis of the Thrombin Receptor Antagonist -...l presented today at the,American Heart Associatio...
Other Medicine Technology:Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin 2Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin 3Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin 4SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 2SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 3SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 4SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 5SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 6SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 7
(Date:11/28/2009)...pirits, recognize signs of depression , ,...eniors, the holiday season can trigger melancholy ... health issues or worry about money problems, acco...help overcome the seasonal blues, the AGS Foundati...: , Get out and socialize or invite family and f...
(Date:11/27/2009)... The Gymboree Corporatio...FO/COO, will present at the NASDAQ OMX 23rd Invest...el in London, England, on Wednesday, December 2, 2...broadcast of The Gymboree Corporation,s presentati...e.com, click on "Our Company" at the bottom of the...
(Date:11/27/2009)...sion vehicles may reduce future disease burden, re...hDay News) -- Encouraging city dwellers to walk an...reater public health benefits than increased used ...und. , The study compared the projected health ...t scenarios for London, England, and Delhi, India:...
(Date:11/27/2009)...ist manufacturers who use medical load cells at th...ollars by bringing in technology partner Flintec e...pro-active medical manufacturers are calling in Fl...eir projects, ensuring that progress will not be c...ally outdated technology. , ...
(Date:11/26/2009)...trathiomolybdate (TM) has been shown in studies to...a disease caused by an overload of copper, and cer...little, however, is known about how the drug works...rthwestern University researchers now has provided...re of TM bound to copper-loaded metallochaperones....
Breaking Medicine News(10 mins):Health News:Seniors May Need Help Overcoming Holiday Blues 2Health News:More Foot Power, Less Car Pollution Best for Health 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Research sheds light on workings of anti-cancer drug 2Health News:Research sheds light on workings of anti-cancer drug 3
...8 Perhaps signaling,donors, fears of a weakening ...c giving for health care in the United States fell...nadian rate of growth in donations to,health care ...stems in both countries are relying more,and more ...
... the non-surgical solution to rejuvenate, restore ...el, MD, is revolutionizing,the field of aesthetic ...e,procedure that restores and improves the appeara... Dr. Trokel, a cosmetic surgeon, the face is like ...
...S, HOME PHOTOS HELP IDENTIFY ASTHMA TRIGGERS , (Mo...me photography may be a more cost-effective altern...a and allergy triggers. Researchers from Truman Me... of areas in their home using a disposable camera....
... ABUSE BY US TROOPS IN IRAQ TWICE NATIONAL AVERAGE...nce of tobacco use by US military deployed to Iraq...er Michael A. Wilson of the United States Navy sur...nt) of the Marines and sailors surveyed used some ...
...atient Advocates Link Underrepresentation of,Minor... HOUSTON, Oct. 28 What is keeping so many,America...m taking part in,medical studies for diseases from...representation of women, older,adults, and minorit...
.... 28 URAC,s Board of,Directors has approved quali...orkers, Compensation and Property and Casualty Pha...t addition to URAC,s Pharmacy Quality,Management(R...y URAC,s,Pharmacy Accreditation Advisory Group, wh...
Other Medicine News:Health News:Growth Rate of U.S. Giving for Health Care Falls More Than 50 Percent in 2007 But Rises Almost Threefold in Canada, According to Association for Healthcare Philanthropy's Annual 'Report on Giving' 2Health News:Growth Rate of U.S. Giving for Health Care Falls More Than 50 Percent in 2007 But Rises Almost Threefold in Canada, According to Association for Healthcare Philanthropy's Annual 'Report on Giving' 3Health News:The Y Lift 2Health News:New research about chronic lung disease presented at CHEST 2008 2Health News:New research about chronic lung disease presented at CHEST 2008 3Health News:New research about chronic lung disease presented at CHEST 2008 4Health News:New research about chronic lung disease presented at CHEST 2008 5Health News:New research about chronic lung disease presented at CHEST 2008 6Health News:New research about chronic lung disease presented at CHEST 2008 7Health News:CHEST 2008: New research related to tobacco use 2Health News:Town Hall Meeting on Inequities in Clinical Trials Documents Ongoing 'Tuskegee Effect' When Recruiting Minorities for Research Studies 2Health News:Town Hall Meeting on Inequities in Clinical Trials Documents Ongoing 'Tuskegee Effect' When Recruiting Minorities for Research Studies 3Health News:Town Hall Meeting on Inequities in Clinical Trials Documents Ongoing 'Tuskegee Effect' When Recruiting Minorities for Research Studies 4Health News:Town Hall Meeting on Inequities in Clinical Trials Documents Ongoing 'Tuskegee Effect' When Recruiting Minorities for Research Studies 5Health News:URAC Introduces New Pharmacy Benefit Management Accreditation for Workers' Compensation and Property and Casualty Programs 2
Maxenon Xi 300
TrueView Sport
TrueView Classic
High Lite Sport
Medicine Products: